BofA Maintains Buy Rating on Merus (MRUS), Lifts PT

finance.yahoo.com/news/bofa-maintains-buy-rating-merus-200027682.html

In This Article:
On Friday, BofA increased its price target for Merus (NASDAQ:MRUS) to $92 from $70, while maintaining a Buy rating on the stock.
The decision follows Merus' highly favorable Phase 2 trial results for the combination of petosemtamab and pembrolizumab in treating…

This story appeared on finance.yahoo.com, 2025-05-25 20:00:27.
The Entire Business World on a Single Page. Free to Use →